Cloudbreak Pharma signs share subscription deal for up to US$15 million with ARC Group unit

  • Cloudbreak Pharma entered a share subscription deal for up to USD 15 million of new shares with ARC Group International.
  • Issuance can occur in multiple drawdowns over 12 months, capped at 167,778,574 shares under an existing general mandate.
  • Pricing set at 93% of average closing bid over a 15-day pricing period, subject to a floor of HKD 1.03.
  • Maximum net proceeds estimated at USD 14.51 million, earmarked for R&D, PRC bank loan repayment, working capital.
  • Commitment fee set at USD 0.3 million in cash, with 60% payable within five business days.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260618-12209179), on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.